company background image
PIRS logo

Pieris Pharmaceuticals NasdaqCM:PIRS 주식 보고서

최종 가격

US$16.98

시가총액

US$22.8m

7D

-0.1%

1Y

-19.6%

업데이트

04 Nov, 2024

데이터

회사 재무

Pieris Pharmaceuticals, Inc.

NasdaqCM:PIRS 주식 보고서

시가총액: US$22.8m

PIRS 주식 개요

생명공학 회사인 피어리스 제약은 생명공학 애플리케이션을 발굴하고 개발하는 회사입니다.

PIRS 기본 분석
눈송이 점수
가치 평가2/6
미래 성장0/6
과거 실적0/6
재무 상태4/6
배당금0/6

Pieris Pharmaceuticals, Inc. 경쟁사

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Pieris Pharmaceuticals
과거 주가
현재 주가US$16.98
52주 최고치US$23.20
52주 최저치US$6.20
베타0.67
11개월 변경4.44%
3개월 변경 사항2.12%
1년 변경 사항-19.59%
33년 변화-94.88%
5년 변화-94.63%
IPO 이후 변화-91.84%

최근 뉴스 및 업데이트

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Recent updates

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15
Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31
Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10
Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15
We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05
Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19
We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22
Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01
Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08
Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01
We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28
How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

주주 수익률

PIRSUS BiotechsUS 마켓
7D-0.1%-1.4%-1.9%
1Y-19.6%20.2%30.4%

수익률 대 산업: PIRS 지난 1년 동안 20.2 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: PIRS 지난 1년 동안 30.4 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is PIRS's price volatile compared to industry and market?
PIRS volatility
PIRS Average Weekly Movement6.0%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

안정적인 주가: PIRS 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: PIRS 의 주간 변동성은 지난 1년 동안 16% 에서 6% 로 감소했습니다.

회사 소개

설립직원CEO웹사이트
200148Steve Yoderwww.pieris.com

생명공학 회사인 피어리스 파마슈티컬스는 생명공학 응용 분야를 발굴하고 개발하는 회사입니다. 이 회사는 4-1BB 이중특이성 면역항암제(IO) 프로그램 개발에 주력하고 있습니다. 임상 파이프라인은 PD-L1과 4-1BB를 표적으로 하는 이중특이성 마브칼린 화합물인 S095012(PRS-344), 레 라보라토아 세르비에르 및 국제연구기관 세르비에르와 제휴한 이중특이성 항체-안티칼린 화합물인 SGN-BB228(PRS-346), 화이자와 제휴한 CD228과 4-1BB를 표적으로 하는 CD228 x 4-1BB 이중항체-안티칼린 화합물인 BOS-342(PRS-342) 등 IO 이중특이성으로 구성돼 있다.와 제휴하여 개발 중인 GPC3 및 4-1BB를 표적으로 하는 GPC3 x 4-1BB 이중 특이적 마브칼린 화합물인 BOS-342(PRS-342)와 보스턴 파마슈티컬스와 제휴하여 1상 연구를 진행 중인 BOS-342(PRS-342)를 보유하고 있습니다.

Pieris Pharmaceuticals, Inc. 기본 사항 요약

Pieris Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
PIRS 기본 통계
시가총액US$22.84m
수익(TTM)-US$23.82m
수익(TTM)US$20.87m

1.1x

P/S 비율

-0.9x

P/E 비율

PIRS 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
PIRS 손익 계산서(TTM)
수익US$20.87m
수익 비용US$16.02m
총 이익US$4.85m
기타 비용US$28.67m
수익-US$23.82m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)-18.04
총 마진23.26%
순이익 마진-114.11%
부채/자본 비율0%

PIRS 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기